| Literature DB >> 22424151 |
Michael Oster1, Eduard Murani, Cornelia C Metges, Siriluck Ponsuksili, Klaus Wimmers.
Abstract
BACKGROUND: In rodent models and in humans the impact of gestational diets on the offspring's phenotype was shown experimentally and epidemiologically. Adverse environmental conditions during fetal development provoke an intrauterine adaptive response termed 'fetal programming', which may lead to both persistently biased responsiveness to extrinsic factors and permanent consequences for the organismal phenotype. This leads to the hypothesis that the offspring's transcriptome exhibits short-term and long-term changes, depending on the maternal diet. In order to contribute to a comprehensive inventory of genes and functional networks that are targets of nutritional programming initiated during fetal life, we applied whole-genome microarrays for expression profiling in a longitudinal experimental design covering prenatal, perinatal, juvenile, and adult ontogenetic stages in a porcine model. Pregnant sows were fed either a gestational low protein diet (LP, 6% CP) or an adequate protein diet (AP, 12% CP). All offspring was nursed by foster sows receiving standard diets. After weaning, all offspring was fed standard diets ad libitum.Entities:
Mesh:
Year: 2012 PMID: 22424151 PMCID: PMC3342123 DOI: 10.1186/1471-2164-13-93
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
No. of expressed probe-sets, filtered probe-sets, and regulated probe-sets of LP and AP offspring at distinct developmental stages and periods
| No. of expressed probe-sets | No. of filtered probe-sets | No. of total regulated probe-sets | No. of regulated probe-sets private to LP offspring | No. of regulated probe-sets private to AP offspring | No. of commonly regulated probe-sets of LP and AP offspring (intersection) |
|---|---|---|---|---|---|
| 12,650 | 7,937 | 1,001 (541 up, 460 down) | |||
| 12,005 | 9,099 | 1 (0 up, 1 down) | |||
| 12,307 | 8,250 | 483 (214 up, 269 down) | |||
| 11,784 | 8,943 | 2,084 (952 up, 1,132 down) | |||
| 13,357 | 10,293 | 8,166 (3,731 up, 4,435 down) | 1,042 (384 up, 658 down) | 1,034 (503 up, 531 down) | 6,090 (2,844 up, 3,246 down) |
| 13,359 | 10,317 | 8,329 (4,118 up, 4,211 down) | 881 (423 up, 458 down) | 991 (448 up, 543 down) | 6,457 (3,247 up, 3,210 down) |
| 12,637 | 8,892 | 6,612 (2,810 up, 3,803 down) | 1,959 (834 up, 1,125 down) | 1,549 (697 up, 852 down) | 3,104 (1,279 up, 1,825 down) |
Developmental period 1 indicates the comparisons between stages 94 dpc and 1 dpn; Developmental period 2 indicates the comparisons between stages 1 dpc and 28 dpn; Developmental period 3 indicates the comparisons between stages 28 dpc and 188 dpn; 'Up' indicates higher expression values of later stages, 'down' indicates lower expression values at later stages.
Figure 1Number of regulated probe-sets in liver tissue. The numbers at the horizontal arrows indicate the quantity of probe-sets significantly regulated between the adjacent ontogenetic stages in either AP or LP offspring, whereas the numbers in the intersections indicate the quantity of probe-sets commonly regulated between stages in AP and LP offspring. The numbers at vertical arrows are the number of probe-sets differentially expressed between AP and LP offspring at the same ontogenetic stage. (Arrows between boxes show direction of the comparison; small arrows indicate up and down regulation, respectively).
Significantly regulated transcripts of metabolic pathways in liver tissue within different ontogenetic stages (Ingenuity Pathway Analysis).
| Ontogenetic stage | Regulated pathway | Direction of regulation | No. of regulated genes | Genes involved in pathway | |
|---|---|---|---|---|---|
| 94 dpc | Wnt signaling | up | 1.20*E-2 | 9 | ACVR1, CSNK1G3, FZD4, FZD6, MAP3K7, MMP7, TCF4, TCF7L2, WNT5A |
| Mitotic roles of Polo-like kinase | down | 5.15*E-8 | 11 | CCNB1, CCNB2, CDC23, CDC25B, CDK1, FZR1, SP90AA1, KIF11, PLK1, PPP2R1B, PTTG1 | |
| G1/S checkpoint regulation | down | 2.76*E-5 | 8 | CCND2, CCND3, CCNE1, CDK4, E2F1, E2F4, RB1, TFDP1 | |
| G2/M DNA damage checkpoint regulation | down | 1.53*E-3 | 5 | CCNB1, CCNB2, CDC25B, CDK1, PLK1 | |
| 1 dpn | - | - | - | - | - |
| 28 dpn | Complement system | up | 2.07*E-5 | 5 | C4B, C5, C6, C9, CD55 |
| G1/S checkpoint regulation | down | 2.49*E-2 | 3 | CDKN1B, HDAC11, TGFB3 | |
| 188 dpn | VEGF signaling | up | 2.80*E-4 | 12 | ACTA2, AKT3, BCL2, EIF2B1, KDR, MAPK1, MRAS, PIK3R3, PRKCB, RRAS2, VCL, VEGFC |
| mTOR signaling | up | 6.29*E-3 | 13 | AKT3, EIF3B, EIF4B, MAPK1, MRAS, PIK3R3, PPP2CB, PRKAB2, PRKCB, RHOJ, RRAS2, TSC1, VEGFC | |
| Synthesis and degradation of ketone bodies | up | 1.18*E-3 | 4 | ACAA1, BDH1, HADHA, HADHB | |
| Bile acid synthesis | up | 3.33*E-3 | 7 | ACAA1, ADH5, ADHFE1, ALDH7A1, HADHA, HADHB, LIPA | |
| Fatty acid elongation in mitochondria | up | 4.81*E-3 | 4 | ACAA1, AUH, HADHA, HADHB | |
| Glucocorticoid receptor signaling | up | 3.99*E-2 | 17 | AKT3, BCL2, CCL2, GTF2A2, GTF2B, GTF2E2, HSP90AB1, HSPA1B, IL1RN, MAPK1, MRAS, NCOR1, PBX1, PIK3R3, RRAS2, TAF4, VCAM1 | |
| Val, Leu, Ile degradation | up | 8.32*E-3 | 8 | ACAA1, ACAD10, ALDH7A1, AUH, BCKDHB, HADHA, HADHB, HIBADH | |
| Biosynthesis of steroids | down | 7.65*E-3 | 5 | CYP24A1, CYP7B1, DHCR7, FDFT1, MVD |
The comparison between the dietary gestational protein diets (LP vs. AP) is shown in dependence of the regulatory direction (up or down).
Significantly regulated transcripts of metabolic pathways in liver tissue between two ontogenetic stages within one dietary group (Ingenuity Pathway Analysis)
| Ontogenetic comparison | Diet | Regulated pathway | Direction of regulation | No. of regulated genes | Genes involved in pathway | |
|---|---|---|---|---|---|---|
| 94 dpc vs. 1 dpn | AMPK signaling | up | 6.96*E-3 | 8 | AKT2, INSR, PIK3C2A, PIK3R1, PPM1B, PRKAA1, PRKACB, RAC1 | |
| Mitotic roles of Polo- like kinase | down | 3.25*E-4 | 7 | CCNB1, CCNB2, CDC25B, CHEK2, KIF11, PLK4, PTTG1 | ||
| Pyrimidine metabolism | down | 2.52*E-3 | 10 | CAD, DCTD, DKC1, POLQ, POLR3E, POLR3K, RFC5, RRM1, TYMS, UCK2 | ||
| G2/M DNA damage checkpoint regulation | down | 2.04*E-4 | 6 | CCNB1, CCNB2, CDC25B, CHEK2, UBC, YWHAE | ||
| Purine metabolism | up | 9.20*E-3 | 12 | DDX39, PNPT1, POLA2, POLE2, POLR1B, POLR1C, POLR2I, RFC3, RRM2, RRM2B, RUVBL1, RUVBL2 | ||
| Pyrimidine metabolism | up | 6.15*E-7 | 14 | CTPS, PNPT1, POLA2, POLE2, POLR1B, POLR1C, POLR2I, PUS1, RFC3, RRM2, RRM2B, TXNRD1, TYMS, UCK2 | ||
| Mitotic roles of Polo- like kinase | up | 7.55*E-5 | 7 | ANAPC4, CDC27, CDK1, ESPL1, FZR1, PPP2R1B, PTTG1 | ||
| G2/M DNA damage checkpoint regulation | up | 3.09*E-2 | 3 | CDK1, CHEK1, YWHAZ | ||
| Wnt signaling | down | 4.02*E-2 | 9 | AKT3, FZD5, MMP7, NLK, SOX4, TCF3, TCF4, TCF7L2, WNT5A | ||
| 1 dpn vs. 28 dpn | AMPK signaling | up | 4.26*E-3 | 8 | AK1, CPT1A, EIF4EBP1, HMGCR, MAPK14, NOS3, PRKAA2, PRKAB2 | |
| mTOR signaling | up | 1.89*E-2 | 7 | EIF3F, EIF3G, EIF4EBP1, FNBP1, GNB1L, PRKAA2, PRKAB2 | ||
| Val, Leu, Ile degradation | down | 6.40*E-3 | 6 | ACAD8, ACADL, ACADSB, BCAT1, DBT, MCCC2 | ||
| Val, Leu, Ile degradation | up | 7.12*E-8 | 11 | ACADSB, ACAT1, ACAT2, ALDH1A1, AUH, BCKDHB, GCDH, HMGCL, HMGCS1, MCCC2, MCEE | ||
| Fatty acid metabolism | up | 3.23*E-3 | 8 | ACADSB, ACAT1, ACAT2, ALDH1A1, AUH, CYP51A1, GCDH, PECI | ||
| Synthesis and degradation of ketone bodies | up | 1.76*E-6 | 5 | ACAT1, ACAT2, BDH2, HMGCL, HMGCS1 | ||
| Biosynthesis of steroids | up | 3.27*E-4 | 5 | CYP24A1, FDPS, HMGCR, IDI1, SC5DL | ||
| Glucocorticoid receptor signaling | up | 3.57*E-3 | 12 | CDKN1C, CXCL3, IL10, MAP3K1, NCOA2, NFKBIB, NR3C1, POLR2B, PRKACB, RRAS2, SLPI, SMARCA4 | ||
| G1/S checkpoint regulation | down | 2.22*E-2 | 4 | CCNE1, CDC25A, CDKN1A, E2F3 | ||
| 28 dpn vs. 188 dpn | AMPK signaling | up | 1.50*E-3 | 10 | INSR, MAPK12, PPAT, PPM1A, PPP2CA, PPP2R3A, PRKAA2, SMARCA2, SRC, STK11 | |
| Fatty acid metabolism | up | 1.28*E-2 | 8 | ACADSB, ALDH1A1, CYP1B1, CYP2D6, CYP3A4, CYP4A11, CYP4B1, PECI | ||
| Mitotic roles of Polo- like kinase | down | 8.33*E-3 | 7 | ANAPC5, CDK1, PLK1, PLK2, PPP2R1B, SLK, WEE1 | ||
| VEGF signaling | down | 7.3*E-3 | 9 | AKT3, BCL2, KDR, NOS3, PRKCB, RAC2, RRAS, VCL, VEGFC | ||
| Val, Leu, Ile degradation | up | 1.07*E-2 | 7 | ACAA1, ACAT1, ALDH1B1, AUH, ECH1, IVD, IWS1 | ||
| Fatty acid elongation in mitochondria | up | 2.05*E-2 | 3 | ACAA1, AUH, ECH1 | ||
| mTOR signaling | up | 2.65*E-2 | 10 | AKT3, DDIT4, EIF4B, EIF4G3, PPP2R1B, PRKAB2, PRKAG1, PRKAG2, TSC1, VEGFA | ||
| Actin cytoskeleton signaling | down | 7.99*E-5 | 24 | ACTB, ACTR2, ARPC4, ARPC1A, CD14, CFL1, F2R, FGD1, LBP, MAP2K1, | ||
| MYH9, NCKAP1, PAK2, PIK3C3, PIK3C2A, PIK3R4, PIKFYVE, PPP1R12A, RDX, ROCK1, ROCK2, TMSB4X, TMSL3, WASF1 | ||||||
| RhoA signaling | dow | 5.05*E-3n | 12 | ACTB, ACTR2, ARHGAP1, ARPC4, ARPC1A, CFL1, PIKFYVE, PPP1R12A, RDX, ROCK1, ROCK2, WASF1 | ||
| Rac signaling | down | 4.34*E-3 | 12 | ACTR2, ARPC4, ARPC1A, CFL1, MAP2K1, NCKAP1, PAK2, PIK3C3, PIK3C2A, PIK3R4, PIKFYVE, WASF1 | ||
| Complement system | down | 2.17*E-2 | 5 | C2, C7, C9, CFB, MBL2 |
The comparison between the dietary gestational protein diets (LP vs. AP) is shown in dependence of the regulatory direction (up or down).
Figure 2Regulated pathways in liver tissue between ontogenetic stages and diets. Listed pathways between AP stages (white boxes) indicate the appropriate ontogenetic development, which does not take place in the LP offspring (black boxes) at the corresponding developmental period. Pathways between the LP stages indicate processes and metabolic regulation, which occur in the LP offspring but not in the AP offspring in the corresponding developmental period. The differences in gene regulation dependent on diet and ontogenetic stage indicate fetal programming in terms of developmental and metabolic disorders (arrows between boxes show direction of the comparison; small arrows indicate up and down regulation, respectively; PLK, Polo-like kinase; VEGF, Vascular endothelial growth factor, mTOR, mammalian target of rapamycin; AMPK, AMP-activated protein kinase; RhoA, Ras homolog gene family, member A; Rac, Ras-related C3 botulinum toxin substrate; FA, Fatty acid)
Comparison of microarray data and qRT-PCR of selected transcripts
| Gene name | Microarray | qRT-PCR # | Correlation ## | ||||
|---|---|---|---|---|---|---|---|
| CCND2 | 0.022 | -1.25 | down | 0.0001 | -1.83 | down | 0.47 * |
| NCAPG | 0.019 | -1.73 | down | 0.003 | -1.58 | down | 0.47 * |
| MGMT | 0.031 | +1.12 | up | 0.011 | +1.32 | up | 0.53 ** |
| GADD45B | 0.669 | -1.08 | n.r. | 0.522 | +1.17 | n.r | 0.68 *** |
| SDHB | 0.0006 | -1.19 | down | 0.028 | -1.30 | down | 0.71 *** |
| CCND2 | 0.711 | -1.06 | n.r. | 0.651 | -1.09 | n.r. | 0.46 * |
| PPARGC1A | 0.745 | -1.03 | n.r. | 0.761 | -1.04 | n.r. | 0.67 *** |
| PRKAA1 | 0.0004 | -1.68 | down | 0.027 | -1.40 | down | 0.77 *** |
| PRKAA2 | 0.009 | -1.36 | down | 0.095 | -1.25 | down | 0.10 |
| PPARGC1A | 0.126 | -1.35 | n.r. | 0.105 | -1.36 | n.r. | 0.86 *** |
CCND2 - cyclin D2; NCAPG - non-SMC condensin I complex, subunit G; MGMT - O-6-methylguanine-DNA methyltransferase; GADD45B - growth arrest and DNA-damage-inducible, β ; SDHB - succinate dehydrogenase complex, subunit B, iron sulfur (Ip); PPARGC1A - Peroxisome proliferator activated receptor γ coactivator-1α; PRKAA1 - 5'-AMP-activated protein kinase, catalytic α1 chain; PRKAA2 - 5'-AMP-activated protein kinase, catalytic α2 chain *calculated by factorial normalisation on RPL10 expression values; **p-value of pamn' rho; n.r. - not regulated
Figure 3Experimental design.
Primer used to verify microarray experiments in liver tissue by qRT-PCR
| Gene name | Probe-set ID | Sequence 5' - 3' | T(°C) | Size (bp) |
|---|---|---|---|---|
| CCND2 | Ssc.15749.1.S1_at | For AGGAGCAGATTGAGGTCGTG | 86 | 185 |
| Rev CAACCAGAGAGAAGGAAGGAGA | ||||
| NCAPG | Ssc.28512.1.S1_at | For CTTGTAGATTTGACGAGACCA | 60 | 156 |
| Rev GGCTTTAGTATAGACCCGAAC | ||||
| MGMT | Ssc.19639.1.A1_at | For GCAACTACTCGGGAGGAATG | 88 | 171 |
| Rev CTGCGAACGCTCAGTCTTG | ||||
| GADD45B | Ssc.14764.1.A1_at | For GGACTTAGACTTTGGGACTTG | 60 | 140 |
| Rev GTAAGCCTCCCATCTCTCTT | ||||
| SDHB | Ssc.8939.1.S1_at | For GCAGGACCCGTTCTCTCTGT | 60 | 170 |
| Rev GGTTACAGTCACGTTAGGTTGG | ||||
| PPARGC1A | Ssc.16864.1.S1_at | For GTAAATCTGCGGGATGATGG | 60 | 208 |
| Rev TGGTGGAAGCAGGATCAAAG | ||||
| PRKAA1 | Ssc.8107.1.A1_at | For TTGTTAATTTCATAAACTTTGCTTC | 60 | 193 |
| Rev GTGCAGCCTTGACATACTC | ||||
| PRKAA2 | Ssc.16257.1.S1_at | For TCTGTAATTCTGTTTTGCCTACGA | 60 | 168 |
| Rev AGCAAGAAGGTGATGCCAAG | ||||
| RPL10* | Ssc.9130.1.A1_at | For CTGTGTTCGTCTTTTCTTCC | 60 | 199 |
| Rev TCATCCACTTTTGCCTTCT |
CCND2 - cyclin D2; NCAPG - non-SMC condensin I complex, subunit G; MGMT - O-6-methylguanine-DNA methyltransferase; GADD45B - growth arrest and DNA-damage-inducible, β ; SDHB - succinate dehydrogenase complex, subunit B, iron sulfur (Ip); PPARGC1A - Peroxisome proliferator activated receptor γ coactivator-1α; PRKAA1 - 5'-AMP-activated protein kinase, catalytic α1 chain; PRKAA2 - 5'-AMP-activated protein kinase, catalytic α2 chain; RPL10 - Ribosomal protein 10; * house keeping gene.